Fig. 2

AUCs at 1, 2, and 3 years of the A TUHP OS model and the B BCLC, C CNLC, D HAP, and E PROSASH-II systems for OS. TUHP targeted therapy for unresectable hepatocellular prognosis, OS overall survival, AUC area under the curve, CI confidence interval, BCLC Barcelona Clinic Liver Cancer, CNLC Chinese Liver Cancer, HAP Hepatoma Arterial Embolization Prognostic system, PROSASH-II Prediction of Survival in Advanced Sorafenib-Treated Hepatocellular Carcinoma-II.